Previous 10 | Next 10 |
PALADIN Study Data Presented at the American Society of Retina Specialists Shows That Post-ILUVIEN, the Percentage of Eyes Receiving One Yearly Treatment or Less Increased 3.2-Fold Compared to Pre-ILUVIEN ATLANTA, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALI...
ATLANTA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with...
ATLANTA, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, announces that Alimera Sciences Europe Limited, its Ireland-based Europe...
Gainers: Trillium Therapeutics (NASDAQ:TRIL) +187%, Vivos Therapeutics (NASDAQ:VVOS) +57%, Xeris Pharmaceuticals (NASDAQ:XERS) +19%, ALX Oncology (NASDAQ:ALXO) +24%, Candel Therapeutics (NASDAQ:CADL) +20%. Losers: Flora Growth (NASDAQ:FLGC) -10%,...
Alimera Sciences, Inc. (ALIM) Q2 2021 Earnings Conference Call August 13, 2021 9:00 AM ET Company Participants Scott Gordon – CORE IR Rick Eiswirth – President and Chief Executive Officer Phil Jones – Chief Financial Officer Conference Call Participants Alex Nowak –...
Image source: The Motley Fool. Alimera Sciences, inc (NASDAQ: ALIM) Q2 2021 Earnings Call Aug 13, 2021 , 9:00 a.m. ET Operator Continue reading For further details see: Alimera Sciences, inc (ALIM) Q2 2021 Earnings Call Transcript
Consolidated Net Revenue of $21.7 Million up 117% vs. Second Quarter of 2020 Consolidated Net Product Revenue of $10.7 Million up 7% vs. Second Quarter of 2020 Net Income of $7.6 Million vs. Net Loss of $2.5 Million in Second Quarter of 2020 End U...
ATLANTA, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera) a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, announces today that it will...
ATLANTA, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences Europe Limited (“Alimera”), a wholly owned subsidiary of Alimera Sciences, Inc., and Tanner Pharma UK Limited (“Tanner”) announced today the initiation of a Named Patient Program for ILUVIEN ® (...
Inflation is here; and that means these groups ought to be on your radar. The best stocks within every sector now. Over 20 new stocks join our 'best stocks' list this week. For further details see: The Stocks To Focus On Today
News, Short Squeeze, Breakout and More Instantly...
Alimera Sciences Inc. Company Name:
ALIM Stock Symbol:
NASDAQ Market:
Alimera Sciences Inc. Website:
2024-07-07 16:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 11:30:02 ET Alliance Global Partners analyst issues NEUTRAL recommendation for ALIM on June 25, 2024 10:23AM ET. The previous analyst recommendation was Buy. ALIM was trading at $5.53 at issue of the analyst recommendation. The overall analyst consensus : HOLD...
2024-06-25 07:00:05 ET Yi Chen from H.C. Wainwright issued a price target of $6.00 for ALIM on 2024-06-25 06:08:00. The adjusted price target was set to $6.00. At the time of the announcement, ALIM was trading at $5.54. The overall price target consensus is at $7.25 with...